Receptor News and Research

RSS

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

Yale study finds garlic acts as birth control for mosquitoes

Garlic is not a substance that most people consider an aphrodisiac. It turns out that mosquitoes agree.

11 May 2026

Study links metabolic dysfunction to cognitive impairment in bipolar disorder

While they share similar depressive and cognitive symptoms, the biological underpinnings of bipolar disorder and major depressive disorder are distinct.

11 May 2026

Diabetes, weight-loss drugs not a perfect fit?

Type 2 diabetes affects millions of people worldwide and now a new international study, jointly led by Adelaide University, University of Oxford, ETH Zurich, and Stanford University, has found one in ten people may not be benefiting from common medications used to treat the condition.

11 May 2026

New study reveals how slow-growing cells drive breast cancer relapse

A new study by the Garvan Institute of Medical Research has uncovered a hidden mechanism explaining why breast cancer can return many years after successful treatment.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Exercise or caffeine? Study finds neither clearly beats placebo for mental fatigue

Researchers compare the effects of caffeine and aerobic exercise on mental fatigue in adults.

10 May 2026

Tumors exploit peripheral nerves to support cancer growth and spread

Tumors do not communicate only with immune cells, blood vessels, and stromal tissue. A growing body of evidence suggests that cancer can also co-opt the nervous system, reshaping the tumor microenvironment in ways that support growth, invasion, immune escape, and therapeutic resistance.

10 May 2026

Researchers uncover how bacterial toxin damages colon lining cells to trigger cancer

Since a landmark 2009 study, researchers have known that a common gut bacterium, Bacteroides fragilis, drives colon tumor formation, potentially leading to colorectal cancer, by secreting a toxin that damages the lining of the colon.

8 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

Engineered regulatory T cells offer a path toward immunosuppression-free transplants

Organ transplantation remains the cornerstone treatment for end-stage organ failure. While conventional broad-spectrum immunosuppression effectively controls acute rejection, it fails to address chronic rejection and carries long-term side effects including infection, malignancy, and metabolic disorders.

8 May 2026

Infectious H5N1 virus detected in dairy farm air

Findings from California dairy farms show H5N1 in air and wastewater, indicating overlooked transmission routes and implications for outbreak management.

8 May 2026

People judge GLP-1 users more harshly than dieters

Stigma surrounding GLP-1 weight loss treatments reveals societal biases, impacting individuals' mental health and the effectiveness of obesity interventions.

7 May 2026

GLP-1 drugs may reshape how brain values rewarding foods

A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetite-it directly alters brain circuits that control motivation and reward.

6 May 2026

CGRP inhibitors may reduce glaucoma risk among migraine patients

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published May 6, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

6 May 2026

GLP-1 weight-loss drugs modulate brain reward circuits to suppress eating for pleasure

A National Institutes of Health (NIH)-funded study has found that an emerging class of GLP-1 weight-loss drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain.

6 May 2026

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

6 May 2026

Bariatric surgery outperforms GLP-1 medications for obesity disease remission

Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and most comprehensive real-world comparisons of the two treatments.

6 May 2026